Nurix Therapeutics, Inc. (NRIX)
15.95
-9.87
(-38.23%)
USD |
NASDAQ |
Nov 04, 16:00
15.97
+0.02
(+0.13%)
After-Hours: 07:29
Nurix Therapeutics Debt to Equity Ratio : 0.0675 for Aug. 31, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| August 31, 2026 | 0.0675 |
| May 31, 2026 | 0.1444 |
| February 28, 2026 | 0.122 |
| November 30, 2025 | 0.1034 |
| August 31, 2025 | 0.1517 |
| May 31, 2025 | 0.116 |
| February 28, 2025 | 0.0554 |
| November 30, 2024 | 0.0537 |
| August 31, 2024 | 0.072 |
| May 31, 2024 | 0.0777 |
| February 29, 2024 | 0.1728 |
| November 30, 2023 | 0.1527 |
| August 31, 2023 | 0.0342 |
| May 31, 2023 | 0.0359 |
| Date | Value |
|---|---|
| February 28, 2023 | 0.0389 |
| November 30, 2022 | 0.0394 |
| August 31, 2022 | 0.0387 |
| May 31, 2022 | 0.0544 |
| February 28, 2022 | 0.0515 |
| November 30, 2021 | 0.0381 |
| August 31, 2021 | 0.00 |
| May 31, 2021 | 0.00 |
| February 28, 2021 | 0.00 |
| November 30, 2020 | 0.00 |
| August 31, 2020 | 0.00 |
| May 31, 2020 | -2.732 |
| February 29, 2020 | -0.6905 |
| November 30, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Gilead Sciences, Inc. | 2.012 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.195B |
| Total Liabilities (Quarterly) | 226.99M |
| Shareholders Equity (Quarterly) | 968.31M |
| Current Ratio | 8.442 |
| Net Debt Paydown Yield | -0.10% |